

NANOGEN

B I O P H A R M A C E U T I C A L

Contents

About us:.....	2
MISSION	2
VISION	2
CORE VALUE:.....	2
Contact Details:.....	3
Product Portfolio.....	3
APIs // Active Pharmaceutical Ingredients	3
Current Finished products - Biosimilars.....	3

About us:

Established in 1997, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC has been striving to become a world-class innovative biotechnology company in pharmaceutical industry. We are proud to be the leading company in Asia-Pacific region that successfully researched and developed Active Pharmaceutical Ingredients (APIs) and specific therapeutic products on the foundation of advanced recombinant DNA/protein technology.

After more than 20 years of tireless research, NANOGEN has successfully offered a variety of gene-to-therapy biopharmaceuticals for the treatment of cancer, hepatitis B, hepatitis C, anemia due to chronic renal failure,... Besides, NANOGEN has been inventing and conducting clinical trials on monoclonal antibodies for oncology immunotherapy as well as Covid-19 vaccine and treatment.

Our facilities including 4 Factories and 1 R&D Center are located in 3 provinces of Vietnam with the total area of 73 000 square meters. Our manufacturing systems and processes are operated under strict quality standards of WHO-GMP and TGA-GMP. With the capacity of more than 50 million products each year, NANOGEN has delivered products to 15 countries in Asia, Europe, Africa and America.

Nanogen has 3 fully automated (Grade A/ISO 5) filling lines which can offer clients liquid, lyophilised or pre-filled syringe option for their products.

NANOGEN's main goal is to improve the production process and enhance research activities to manufacture high quality, safe, effective and affordable products for more patients in the world.

MISSION

Innovative biotechnology play a vital role in everything we offer. Our mission is to develop and manufacture safe, effective and affordable biopharmaceuticals for patients. We use novel technology to enhance the drug formulations with better tolerability and safety.

VISION

Our long-term goal is to become one of the leading biopharmaceutical manufacturers in the world and the developer of novel biotherapeutic products. We are committed to protecting the health of more people worldwide.

CORE VALUE:

Distinguish us and guide us to ensure long-term business relationship with our partner.

Contact Details:

NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC

Address:

Lot E2a-1, E2a-2 Saigon Hitech Park, Long Thanh My Ward, Thu Duc City, Ho Chi Minh City, VIETNAM

Lot I-5C Saigon Hitech Park, Tang Nhon Phu A Ward, Thu Duc City, Ho Chi Minh City, VIETNAM

Tel: (+84) 28 7108 9688

Fax: (+84) 283 730 9963

Email: info@nanogenpharma.com/ huongpt@nanogenpharma.com

Website: nanogenpharma.com

Product Portfolio

APIs // Active Pharmaceutical Ingredients

- CHO cells:
 - MABs: Trastuzumab, Bevacizumab, Rituximab, Adalimumab, Omalizumab, Ipilimumab, Nivolumab, and CB6.
 - Other recombinant proteins: DEPO (Darbepoetin alfa), EPO (Erythropoetin alfa), Factor VII, Factor IX, Etanercept
- E. coli:
 - GCSF (Filgrastim), Peg-GCSF (Peg-Filgrastim), Interferon, Peg-Interferon
 - Insulin Human, Insulin Glargin
 - scFV

Protein titre: ~4g/L for Mab, 0.5g/L for other proteins, 3-5 g/L for E.coli products

Current Finished products - Biosimilars

Brand name	Ingredients	Strength
NANOKINE	Erythropoetin alfa	PFS: 2,000 IU/0.5 mL; 4,000 IU/0.5 mL; 10,000 IU/1 mL Vial: 2,000 IU/1 mL; 4,000 IU/1 mL; 10,000 IU/1 mL

Brand name	Ingredients	Strength
PEGNANO	Peg-Interferon alfa – 2a	PFS: 180 mcg/0.5 mL Vial: 180 mcg/1 mL
FICOCYTE	Filgratim	PFS: 30 MU/0.5mL; 48 MU/0.8 mL Vial: 30 MU/1 mL; 48 MU/1.6 mL
PEGCYTE	Peg-Filgrastim	PFS: 6 mg/ 0.5mL; 6 mg/ 0.6 mL
FERONSURE	Interferon alfa – 2a	PFS: 3 MIU/0.5 mL Vial: 3 MIU/1 mL
FACEPTOR	Trastuzumab	Vial: 150 mg; 440mg